Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study.
Xue-Ping Huang, Yi-Juan Liu, Shao-Wei Lin...
https://pubmed.ncbi.nlm.nih.gov/39086752/Actively Recruiting
Led by Yongquan Shi · Updated on 2026-10-27
448
Participants Needed
24
Research Sites
21 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of two different treatment regimens to eradicate Helicobacter pylori infection. This trial compares a dual therapy using linralase glutarate capsules combined with amoxicillin against a quadruple therapy that includes bismuth. The main goal is to see if the dual therapy is not less effective than the quadruple therapy, while also monitoring patient adherence and side effects. This is a phase 4, randomized, open-label study aimed at first-line treatment of this infection. Participants receive either the dual-drug regimen of linralase glutarate capsules 50 mg twice daily plus amoxicillin 1 g three times daily or the quadruple therapy consisting of esomeprazole 20 mg twice daily, clarithromycin 0.5 g twice daily, amoxicillin 1 g twice daily, and colloidal bismuth subcitrate 200 mg twice daily. Both treatment courses last for 14 days. The study groups are assigned randomly and monitored during and after treatment to assess outcomes. During the study, participants undergo testing to determine the Helicobacter pylori eradication rate 28 days after treatment ends. Researchers also track adverse events during the 14 days of treatment and for 28 days following treatment completion. Participants adherence to the medication regimens is evaluated throughout. The trial includes adults aged 18 to 70 years who meet specific diagnostic and health criteria. The total duration from treatment to outcome measurement spans about 6 weeks, including follow-up assessments.
CONDITIONS
Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection
Y
Yongquan Shi, Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yongquan Shi
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 days
Participants receive either the dual therapy of linralase glutarate capsules with amoxicillin or the bismuth-containing quadruple therapy for 14 days.
Daily medication, with regular monitoring visits
Duration - 28 days
Participants are assessed for Helicobacter pylori eradication and monitored for adverse events up to 28 days after treatment ends.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Xue-Ping Huang, Yi-Juan Liu, Shao-Wei Lin...
https://pubmed.ncbi.nlm.nih.gov/39086752/Zhiqiang Song, Xiuli Zuo, Zhenyu Zhang...
https://pubmed.ncbi.nlm.nih.gov/40908593/Yongquan Shi
Lead Sponsor